AB-201 for HER2-positive advanced stomach or GEJ cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new cell therapy called AB-201 for people with advanced HER2-positive stomach or gastroesophageal cancer who have already tried standard treatments. The goal is to see if AB-201 is safe and can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 or older.
- You have advanced stomach or gastroesophageal junction cancer that tests positive for HER2 (IHC 1+ or higher).
- You have already tried at least 2 previous cancer treatments that did not work or were not tolerated.
- Your general health is good (able to do daily activities without much trouble).
- Your heart, blood counts, liver, and kidney function meet safety levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of anti-cancer medicines for HER2-positive advanced stomach cancer that has already been treated once. It may help shrink tumors and slow the disease by targeting HER2 and blocking tumor blood supply.
This trial tests whether combining different drugs before and after surgery can help people with locally advanced stomach cancer that can't be removed right away. The goal is to see which combination works best to shrink the tumor and improve outcomes.
This study tests ABT-101, a new experimental treatment, in people with advanced solid tumors. A second part specifically looks at people with non-small cell lung cancer (NSCLC) that has HER2 mutations, to see how well the treatment works and how safe it is.
This trial tests a new combination of an anti-HER2 drug (SHR-A1811) plus chemotherapy and an immunotherapy (adebrelimab) for people with untreated advanced stomach cancer. It aims to see if this combination works better than standard treatment.
This trial tests two new antibody drugs (SSGJ-705 and SSGJ-612), alone or combined with chemotherapy, in patients with advanced cancers that have a protein called HER2. The study aims to see if this combination can shrink tumors and help patients live longer.
This Phase 2 trial tests whether SHR-A1811—given with other medicines—works safely and effectively for people with advanced stomach or gastroesophageal junction cancer that has high HER2. It may help shrink tumors or slow cancer growth, especially if previous treatment didn’t work.
Hear when a new Malignant Neoplasm of Stomach, Unspecified trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.